Reversal of Human Immunodeficiency Virus Type 1 IIIB to a Neutralization-Resistant Phenotype in an Accidentally Infected Laboratory Worker with a Progressive Clinical Course

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Virology

• Publication date

  2001-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/jvi.75.5.2246-2252.2001PMID 11160728PMCID PMC114808
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Viral persistence in vivo through selection of neutralizing antibody-escape variants.

  2000cited by this paper
• Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection

  2000cited by this paper
• Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

  2000cited by this paper
• Increased Neutralization Sensitivity and Reduced Replicative Capacity of Human Immunodeficiency Virus Type 1 after Short-Term In Vivo or In Vitro Passage through Chimpanzees

  2000cited by this paper
• Minimal Incidence of Serum Antibodies Reactive with Intact Primary Isolate Virions in Human Immunodeficiency Virus Type 1-Infected Individuals

  1999cited by this paper
• Longitudinal Phenotypic Analysis of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes: Correlation with Disease Progression

  1999cited by this paper
• The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

  1999cited by this paper
• Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys

  1999cited by this paper
• Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression

  1999cited by this paper
• Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors.

  1999cited by this paper
• Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

  1999cited by this paper
• Changes in Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Responsible for the Pathogenicity of a Multiply Passaged Simian-Human Immunodeficiency Virus (SHIV-HXBc2)

  1999cited by this paper
• Will Multiple Coreceptors Need To Be Targeted by Inhibitors of Human Immunodeficiency Virus Type 1 Entry?

  1999cited by this paper
• A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects.

  1999cited by this paper
• Evidence that Antibody-Mediated Neutralization of Human Immunodeficiency Virus Type 1 by Sera from Infected Individuals Is Independent of Coreceptor Usage

  1998cited by this paper
• The antigenic structure of the HIV gp120 envelope glycoprotein

  1998cited by this paper
• CXCR4 as a Functional Coreceptor for Human Immunodeficiency Virus Type 1 Infection of Primary Macrophages

  1998cited by this paper
• Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

  1998cited by this paper
• Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage

  1998cited by this paper
• Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Primary Isolates to Antibodies and CD4-Based Reagents Is Independent of Coreceptor Usage

  1998cited by this paper
• Development of a Neutralizing Antibody Response during Acute Primary Human Immunodeficiency Virus Type 1 Infection and the Emergence of Antigenic Variants

  1998cited by this paper
• Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection.

  1998cited by this paper
• Neutralizing antibodies are positively associated with CD4+ T‐cell counts and T‐cell function in long‐term AIDS‐free infection

  1998cited by this paper
• Role of gp41 glycosylation sites in the biological activity of human immunodeficiency virus type 1 envelope glycoprotein.

  1998cited by this paper
• Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

  1998cited by this paper
• Core structure of gp41 from the HIV envelope glycoprotein.

  1997cited by this paper
• Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals

  1997cited by this paper
• Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus

  1997cited by this paper
• Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off

  1997cited by this paper
• Atomic structure of the ectodomain from HIV-1 gp41

  1997cited by this paper
• Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.

  1997cited by this paper
• HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.

  1995cited by this paper
• Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera

  1995cited by this paper
• Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.

  1995cited by this paper
• Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.

  1995cited by this paper
• Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period

  1995cited by this paper
• Increasing genotypic and phenotypic selection from the original genomic RNA populations of HIV‐1 strains LAI and MN (NM) by peripheral blood mononuclear cell culture, B‐cell-line propagation and T‐cell-line adaptation

  1995cited by this paper
• Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein

  1995cited by this paper
• Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization

  1994cited by this paper
• Macrophage‐tropic HIV‐1 variants: initiators of infection and AIDS pathogenesis?

  1994cited by this paper
• Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.

  1994cited by this paper
• Viral Variability and Serum Antibody Response in a Laboratory Worker Infected with HIV Type 1 (HTLV Type IIIB)

  1994cited by this paper
• Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated

  1994cited by this paper
• Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system

  1994cited by this paper
• MEGA: Molecular Evolutionary Genetics Analysis software for microcomputers

  1994cited by this paper
• Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1

  1994cited by this paper
• Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion.

  1994cited by this paper
• Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

  1994cited by this paper
• Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.

  1994cited by this paper
• Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

  1993cited by this paper
• Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker.

  1993cited by this paper
• Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies

  1993cited by this paper
• Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies.

  1993cited by this paper
• Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population

  1992cited by this paper
• Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule

  1992cited by this paper
• Autologous HIV‐1 Neutralizing Antibodies: Emergence of Neutralization‐Resistant Escape Virus and Subsequent Development of Escape Virus Neutralizing Antibodies

  1992cited by this paper
• Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture

  1991cited by this paper
• Macrophage-active colony-stimulating factors enhance human immunodeficiency virus type 1 infection in bone marrow stem cells.

  1991cited by this paper
• An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.

  1991cited by this paper
• Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus.

  1991cited by this paper
• Rapid and simple method for purification of nucleic acids

  1990cited by this paper
• Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV p24gag.

  1989cited by this paper
• An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies

  1989cited by this paper
• Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity

  1988cited by this paper
• Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers.

  1988influential reference

• A New Type of Nonsuppressible Viremia Produced by HIV-Infected Macrophage

  2025cites this paper
• CRL4-DCAF1 Ubiquitin Ligase Dependent Functions of HIV Viral Protein R and Viral Protein X

  2024cites this paper
• HIV-1 Vpr-induced DNA damage activates NF-κB through ATM-NEMO independent of cell cycle arrest

  2024cites this paper
• HIV Vpr activates a nucleolar-specific ATR pathway to degrade the nucleolar stress sensor CCDC137

  2024cites this paper
• HIV-1 Vpr-induced DNA damage activates NF-κB through ATM-NEMO independent of cell cycle arrest

  2023cites this paper
• HIV-1 Vpr-induced DNA damage activates NF-κB independent of cell cycle arrest and 1 CRL4A DCAF1 engagement 2

  2023cites this paper
• Triazolopyrimidine derivatives: An updated review on recent advances in synthesis, biological activities and drug delivery aspects.

  2023cites this paper
• Host Restriction Factors Modulating HIV Latency and Replication in Macrophages

  2022cites this paper
• Host Restriction Factors Modulating HIV Latency and Replication in Myeloid Cells

  2021cites this paper
• Inhibition of polo-like kinase 1 (PLK1) facilitates reactivation of gamma-herpesviruses and their elimination

  2021cites this paper
• HIV-1 Vpr Induces Widespread Transcriptomic Changes in CD4+ T Cells Early Postinfection

  2021cites this paper
• Vpr Is a VIP: HIV Vpr and Infected Macrophages Promote Viral Pathogenesis

  2020cites this paper
• Inhibition of Polo-like kinase 1 (PLK1) to facilitate the reactivation and elimination of latent gamma-herpesviruses

  2020cites this paper
• Nucleolar protein NOP2/NSUN1 suppresses HIV-1 transcription and promotes viral latency by competing with Tat for TAR binding and methylation

  2020cites this paper
• Illuminating the Role of Vpr in HIV Infection of Myeloid Cells

  2019cites this paper
• Concomitant Enhancement of HIV-1 Replication Potential and Neutralization-Resistance in Concert With Three Adaptive Mutations in Env V1/C2/C4 Domains

  2019cites this paper
• Vpr and Its Cellular Interaction Partners: R We There Yet?

  2019cites this paper
• A Single Substitution in gp41 Modulates the Neutralization Profile of SHIV during In Vivo Adaptation.

  2019cites this paper
• Movements of HIV-1 genomic RNA-APOBEC3F complexes and PKR reveal cytoplasmic and nuclear PKR defenses and HIV-1 evasion strategies.

  2016cites this paper
• HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds

  2016cites this paper
• Activation of the DNA Damage Response Is a Conserved Function of HIV-1 and HIV-2 Vpr That Is Independent of SLX4 Recruitment

  2016cites this paper
• HIV-1 Vpr degrades the HLTF DNA translocase in T cells and macrophages

  2016cites this paper
• Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein

  2015cites this paper
• Vpr Enhances Tumor Necrosis Factor Production by HIV-1-Infected T Cells

  2015cites this paper
• A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the “Antigen Capsid-Incorporation” strategy

  2014cites this paper
• Evolution of human immunodeficiency virus type 1 clade C envelope V1-V5 region during disease progression in non-human primate model

  2013cites this paper
• The Evolution of SIV in Primates and the Emergence of the Pathogen of AIDS

  2013cites this paper
• HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity

  2013cites this paper
• Interactions VIH-hôte : modulation de l'expression de facteurs cellulaires

  2012cites this paper
• against recently transmitted subtype B HIV-1 variants from early and late in the 2

  2011cites this paper
• Longer V1V2 Region with Increased Number of Potential N-Linked Glycosylation Sites in the HIV-1 Envelope Glycoprotein Protects against HIV-Specific Neutralizing Antibodies

  2011cites this paper
• Activity of Broadly Neutralizing Antibodies, Including PG9, PG16, and VRC01, against Recently Transmitted Subtype B HIV-1 Variants from Early and Late in the Epidemic

  2011cites this paper
• Longitudinal Analysis of Early HIV-1-Specific Neutralizing Activity in an Elite Neutralizer and in Five Patients Who Developed Cross-Reactive Neutralizing Activity

  2011cites this paper
• Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity.

  2010cites this paper
• Rapid Escape from Preserved Cross-Reactive Neutralizing Humoral Immunity without Loss of Viral Fitness in HIV-1-Infected Progressors and Long-Term Nonprogressors

  2010cites this paper
• Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.

  2010cites this paper
• Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.

  2009cites this paper
• Infectious diseases: An ill wind for wild chimps?

  2009cites this paper
• A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression

  2009cites this paper
• CHAPTER 5 – Viral and Host Determinants of HIV-1 Disease Progression

  2008cites this paper
• Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.

  2008cites this paper
• Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection

  2008cites this paper
• Neutralization Patterns and Evolution of Sequential HIV Type 1 Envelope Sequences in HIV Type 1 Subtype B-Infected Drug-Naive Individuals

  2008cites this paper
• T cell line passage can select for pre-existing neutralization-sensitive variants from the quasispecies of primary human immunodeficiency virus type-1 isolates.

  2007cites this paper
• Susceptibility of Recently Transmitted Subtype B Human Immunodeficiency Virus Type 1 Variants to Broadly Neutralizing Antibodies

  2007cites this paper
• A model of directional selection applied to the evolution of drug resistance in HIV-1.

  2007cites this paper
• Neutralization kinetics of sensitive and resistant subtype B primary human immunodeficiency virus type 1 isolates

  2006influential citation
• AIDS vaccine development and challenge viruses: getting real.

  2006cites this paper
• AIDS/HIV, Molecular and Cell Biology

  2006cites this paper
• The humoral immune response to HIV-1: Consequences for vaccine design.

  2005cites this paper
• Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors

  2005cites this paper
• V3: HIV's Switch-Hitter

  2005cites this paper
• Vossiuspers UvA is een imprint van Amsterdam University Press. Deze uitgave is totstandgekomen onder auspiciën van de Universiteit van Amsterdam.

  2005cites this paper
• HIV-1 infection in children: a clinical and immunologic overview.

  2005cites this paper
• Impairment of HIV-Specific Immune Effector Cell Function

  2005cites this paper
• Increased Sensitivity to CD4 Binding Site-Directed Neutralization following In Vitro Propagation on Primary Lymphocytes of a Neutralization-Resistant Human Immunodeficiency Virus IIIB Strain Isolated from an Accidentally Infected Laboratory Worker

  2004cites this paper
• Live attenuated HIV vaccines: pitfalls and prospects

  2004cites this paper
• The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.

  2004cites this paper
• Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation

  2003cites this paper
• The author hereby certifies that the use of copyrighted material in the thesis manuscript entitled:

  2003cites this paper
• Cell surface receptors for gammaretroviruses.

  2003cites this paper
• Convergent evolution of SIV env after independent inoculation of rhesus macaques with infectious proviral DNA.

  2003cites this paper
• Widespread Adaptive Evolution in the Human Immunodeficiency Virus Type 1 Genome

  2003cites this paper
• Evolution of coreceptor use and CD4-independence in envelope clones derived from SIVsm-infected macaques.

  2003cites this paper
• Evolution of Two Amino Acid Positions Governing Broad Neutralization Resistance in a Strain of Feline Immunodeficiency Virus over 7 Years of Persistence in Cats

  2003cites this paper
• A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1.

  2003cites this paper
• Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site

  2003cites this paper
• Immunologic control of HIV-1.

  2002cites this paper
• Equine Infectious Anemia Virus Envelope Evolution In Vivo during Persistent Infection Progressively Increases Resistance to In Vitro Serum Antibody Neutralization as a Dominant Phenotype

  2002cites this paper
• Viral persistence: HIV's strategies of immune system evasion.

  2002cites this paper
• A New Cell Line-Based Neutralization Assay for Primary HIV Type 1 Isolates

  2002cites this paper
• Molecular Evolution of Human Immunodeficiency Virus env in Humans and Monkeys: Similar Patterns Occur during Natural Disease Progression or Rapid Virus Passage

  2002influential citation
• Immunology and Evolution of Infectious Disease

  2002cites this paper
• Resistance to Neutralizing Antibody and Expanded Coreceptor Usage Are Associated with Human Immunodeficiency Virus Type 1 Isolates Derived from Chimpanzees with Pathogenic Infections

  2001cites this paper
• Species and Tissue Tropisms of HIV-1 : Molecular Basis and Phenotypic Consequences

  2001cites this paper
• New insights into protective humoral responses and HIV vaccines.

  2001cites this paper
• Feline Immunodeficiency Virus-Infected Cat Sera Associated with the Development of Broad Neutralization Resistance In Vivo Drive Similar Reversions In Vitro

  2001cites this paper
• Virus population dynamics, fitness variations and the control of viral disease: an update.

  2001cites this paper
• Immune evasion strategies of the primate lentiviruses

  2001cites this paper
• Human Immunodeficiency Virus Type 1 IIIB Selected for Replication In Vivo Exhibits Increased Envelope Glycoproteins in Virions without Alteration in Coreceptor Usage: Separation of In Vivo Replication from Macrophage Tropism

  2001cites this paper